That sets the stage for a potential head-to-head competition between Lilly and Eisai, along with its partner Biogen Inc., for leadership in a market expected to rise to billions of dollars as more patients with early Alzheimer’s gravitate to the idea of preventing the loss of memories and brain function. While both drugs’ use may be held back by cost, side effects and moderate effectiveness, experts hope they’ll
pave the way to more powerful successors.
I spent every chance I got in my 20s diving with sharks, so I don’t scare easily. The one thing I am afraid of is losing my mental capacity. Several relations on my mother’s side of the family have suffered from the disease.
My grandmother stopped taking her blood pressure medication, as soon as she felt her mind go. She was a proud woman and decided to let nature take its course rather than be doomed to an uncertain existence as a vegetable.
It stands to reason that anyone who has witnessed how Alzheimer’s steals pieces of the mind in a relentless manner, will be in the market for anything that might slow the disease’s progression.Click HERE to subscribe to Fuller Treacy Money Back to top